Avadel Pharmaceuticals PLC
AVDL11.187USD
+0.107+0.96%
交易中 （美东）报价延迟15分钟
1.08B总市值
亏损市盈率 TTM
关于 Avadel Pharmaceuticals PLC 公司
Avadel Pharmaceuticals PLC 是一家生物制药公司。该公司的产品 LUMRYZ 是一种缓释型羟基丁酸钠，适用于睡前服用一次，用于治疗成人发作性睡病患者的猝倒症或白天过度嗜睡 (EDS)。该公司的方法包括将解决方案应用于药物开发，以解决患者面临的治疗选择问题。该公司的药物输送技术包括 MICROPUMP、LIQUITIME 和 MEDUSA。其 MICROPUMP 技术可用于开发缓释型固体口服剂型药物。其 LIQUITIME 技术可用于开发液体悬浮液剂型的缓释型口服产品，这可能使此类剂型特别适合儿童和/或吞咽药片或胶囊有困难的患者。其 MEDUSA 技术可用于开发缓释型注射剂型药物。
公司简介
公司代码AVDL
公司名称Avadel Pharmaceuticals PLC
上市日期Jan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
员工数量188
证券类型Ordinary Share
年结日Jan 16
公司地址Block 10-1 Blanchardstown Corporate Park
城市DUBLIN
上市交易所NASDAQ Global Market Consolidated
国家Ireland
邮编15
电话35319015201
网址https://www.avadel.com/
公司代码AVDL
上市日期Jan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
收入明细
单位: USD更新时间: 3月3日 周一
单位: USD更新时间: 3月3日 周一
FY2020
FY2019
业务USD
名称
营收
占比
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
地区USD
名称
营收
占比
United States
22.33M
100.00%
Ireland
0.00
0.00%
业务
地区
业务USD
名称
营收
占比
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
14.03%
Tontine Asset Management, LLC
6.32%
Brandes Investment Partners, L.P.
5.85%
The Vanguard Group, Inc.
5.74%
Two Seas Capital LP
5.10%
Other
62.95%
持股股东
持股股东
占比
Janus Henderson Investors
14.03%
Tontine Asset Management, LLC
6.32%
Brandes Investment Partners, L.P.
5.85%
The Vanguard Group, Inc.
5.74%
Two Seas Capital LP
5.10%
Other
62.95%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
28.13%
Investment Advisor
26.80%
Hedge Fund
20.94%
Individual Investor
4.83%
Venture Capital
3.82%
Research Firm
2.59%
Pension Fund
0.47%
Bank and Trust
0.38%
Insurance Company
0.03%
Other
12.03%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
372
85.19M
87.92%
-22.67M
2025Q1
377
85.31M
88.05%
-24.78M
2024Q4
354
86.56M
89.59%
-16.46M
2024Q3
334
81.87M
84.98%
-15.41M
2024Q2
299
81.11M
84.30%
-2.77M
2024Q1
258
76.98M
80.25%
+5.42M
2023Q4
226
62.92M
70.15%
-3.93M
2023Q3
220
60.11M
69.62%
-5.86M
2023Q2
213
57.67M
66.98%
-1.24M
2023Q1
201
54.14M
84.38%
+9.93M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
13.59M
14.03%
-487.88K
-3.47%
Mar 31, 2025
Tontine Asset Management, LLC
6.13M
6.32%
-203.28K
-3.21%
Mar 31, 2025
Brandes Investment Partners, L.P.
5.67M
5.85%
+3.49M
+160.78%
Mar 31, 2025
The Vanguard Group, Inc.
3.88M
4.01%
-52.69K
-1.34%
Mar 31, 2025
Two Seas Capital LP
4.95M
5.1%
+650.00K
+15.13%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.69M
4.84%
-55.04K
-1.16%
Mar 31, 2025
Polar Capital LLP
4.36M
4.5%
-58.24K
-1.32%
Mar 31, 2025
Kotler (Kevin)
3.72M
3.84%
-1.01M
-21.37%
Feb 12, 2024
Vivo Capital, LLC
2.68M
2.77%
--
--
Mar 31, 2025
Wealth Effects LLC
2.37M
2.44%
+24.99K
+1.07%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Pharmaceuticals ETF
2.64%
iShares Neuroscience and Healthcare ETF
1.92%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Nuveen ESG Small-Cap ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.06%
Federated Hermes MDT Small Cap Core ETF
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.05%
查看更多
Invesco Pharmaceuticals ETF
占比2.64%
iShares Neuroscience and Healthcare ETF
占比1.92%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.11%
Invesco Nasdaq Biotechnology ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
Nuveen ESG Small-Cap ETF
占比0.07%
Fidelity Enhanced Small Cap ETF
占比0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
占比0.06%
Federated Hermes MDT Small Cap Core ETF
占比0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.05%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
